Efficacy News and Research

RSS

University of Texas professor recommends three postulates to find probable cause of AD

After more than 100 years following its pathologic description, the cause of Alzheimer's disease (AD) remains unknown. To test the validity of present and future proposals related to the probable cause of AD, three postulates, or necessary conditions, are recommended by Jack de la Torre, MD, PhD, Adjunct Professor of Psychology at the University of Texas, Austin, in an article published in the Journal of Alzheimer's Disease.

20 Jun 2011

New insight into progressive supranuclear palsy

There are new genetic clues on risk factors and biological causes of a rare neurodegenerative disease called progressive supranuclear palsy (PSP), according to a new study from an international genetics team led by researchers from the Perelman School of Medicine at the University of Pennsylvania.

20 Jun 2011

FDA approves NULOJIX

Bristol-Myers Squibb Company announced that the U.S. Food and Drug Administration (FDA) approved NULOJIX, the first selective T-cell costimulation blocker indicated for the prophylaxis of organ rejection in adult patients receiving a kidney transplant, in combination with basiliximab induction, mycophenolate mofetil (MMF), and corticosteroids.

18 Jun 2011

Positive data from Ischemix CMX-2043 Phase 2a trial for peri-operative cardiac ischemia-reperfusion injury

Ischemix today announced positive top line data from a Phase 2a clinical trial of CMX-2043 for the prevention of peri-operative cardiac ischemia-reperfusion injury.

17 Jun 2011

Careful, well-designed studies needed for evaluating patients with MS: SIRF panel

Evaluating patients with multiple sclerosis who have narrowed jugular and azygos veins-and the value of widening those veins with angioplasty-warrants careful, well-designed research, noted members of a Society of Interventional Radiology Foundation's Research Consensus Panel.

17 Jun 2011

VIVUS Avanafil phase 3 trial on erectile dysfunction meets primary endpoints

VIVUS, Inc. today announced that the positive results from REVIVE-RP, a phase 3 clinical trial evaluating the safety and efficacy of the investigational drug avanafil for the treatment of erectile dysfunction (ED),will be presented this afternoon at the 2011 Cancer Survivorship and Sexual Health Symposium in Washington D.C.

17 Jun 2011

Allos Therapeutics reports results from FOLOTYN pivotal trial against peripheral T-cell lymphoma

Allos Therapeutics, Inc. today reported results from a retrospective analysis of data from the Company's pivotal PROPEL trial which suggested that treatment with single-agent FOLOTYN may result in increased response rates and progression-free survival relative to the immediate prior line of therapy in patients with relapsed or refractory peripheral T-cell lymphoma.

17 Jun 2011

Pearl advances PT003 dual combination drug candidate into Phase 2 studies for treatment of COPD

Pearl Therapeutics Inc. today announced the advancement of its dual combination product candidate, PT003 and its individual components, PT001 and PT005 into a series of planned Phase 2 studies in patients with moderate-to-severe COPD.

17 Jun 2011

CTI announces positive results from Phase I-II pixantrone combination study against INHL

Cell Therapeutics, Inc. announced the publication of results posted in the online journal of Cancer of a Phase I-II study that evaluated the safety and efficacy of pixantrone when used in combination with fludarabine, dexamethasone and rituximab replacing mitoxantrone in the standard FND-R regimen with FPD-R among 28 patients with relapsed or refractory indolent non-Hodgkin's lymphoma.

17 Jun 2011

Positive results from etanercept pilot study against dermatomyositis

A multicenter pilot study of etanercept for treatment of dermatomyositis found no major safety concerns and many patients treated with the drug were successfully weaned from steroid therapy.

17 Jun 2011

IITA launches initiative to prevent aflatoxin contamination in African crops

African agricultural research groups led by the International Institute of Tropical Agriculture (IITA) and partners have launched a project seeking to provide farmers with a natural, safe, and cost-effective solution to prevent contamination of maize and peanut by a deadly cancer-causing poison, aflatoxin, in a bid to improve the health and income of families in Nigeria and Kenya.

17 Jun 2011

New Australian drug shows positive response in patients with multiple myeloma blood cancer

Australian monoclonal antibody company, Immune System Therapeutics Limited (IST), today announced it would double patient recruitment in its Phase II trial for a breakthrough antibody treatment for terminal blood cancer.

16 Jun 2011

Adaptimmune melanoma trial opening

Adaptimmune announced today that it has opened a Phase I/II, two cohort, open label clinical trial in metastatic melanoma at Washington University, St. Louis, Missouri.

16 Jun 2011

Enrollment complete in NeurogesX NGX-1998 Phase 2 clinical study for postherpetic neuralgia

NeurogesX, Inc., a biopharmaceutical company focused on developing and commercializing novel pain management therapies, today announced the completion of patient enrollment in its Phase 2 clinical study of NGX-1998, a topical liquid formulation of high-concentration capsaicin, in patients with postherpetic neuralgia (PHN).

16 Jun 2011

Tulane University, VA grant IRB approval for new TIGR Matrix clinical trial in hernia repair

Novus Scientific today announced that Tulane University School of Medicine and Department of Veterans Affairs have granted IRB approval to a new trial: A Study Evaluating Efficacy of TIGR® Matrix Surgical Mesh used in Elective Open Inguinal Hernia Repair.

16 Jun 2011

Large trial of tenofovir gel for women set to begin in South Africa

A 24-month clinical trial looking at the effectiveness of tenofovir gel use among women to reduce the risk of HIV infection is set to begin in South Africa in late July or early August, the Mail & Guardian reports.

16 Jun 2011

Evidence-based practice guidelines for prevention and treatment of frostbite

Frostbite can be a minor injury or a life-threatening condition. In the June issue of Wilderness & Environmental Medicine, a panel of experts has published evidence-based practice guidelines issued by the Wilderness Medical Society (WMS) for the prevention and treatment of frostbite to guide clinicians and disseminate knowledge about best practices.

16 Jun 2011

Efficacy News and Research

University of Texas professor recommends three postulates to find probable cause of AD

New insight into progressive supranuclear palsy

FDA approves NULOJIX

Positive data from Ischemix CMX-2043 Phase 2a trial for peri-operative cardiac ischemia-reperfusion injury

Careful, well-designed studies needed for evaluating patients with MS: SIRF panel

VIVUS Avanafil phase 3 trial on erectile dysfunction meets primary endpoints

Allos Therapeutics reports results from FOLOTYN pivotal trial against peripheral T-cell lymphoma

Pearl advances PT003 dual combination drug candidate into Phase 2 studies for treatment of COPD

CTI announces positive results from Phase I-II pixantrone combination study against INHL

Positive results from etanercept pilot study against dermatomyositis

IITA launches initiative to prevent aflatoxin contamination in African crops

New Australian drug shows positive response in patients with multiple myeloma blood cancer

Adaptimmune melanoma trial opening

Enrollment complete in NeurogesX NGX-1998 Phase 2 clinical study for postherpetic neuralgia

Tulane University, VA grant IRB approval for new TIGR Matrix clinical trial in hernia repair

Large trial of tenofovir gel for women set to begin in South Africa

Evidence-based practice guidelines for prevention and treatment of frostbite

MRE reduces ionizing radiation exposure, detects Crohn's disease as reliably as CT

Antibiotics overprescribed for in home-care patients

Positive results from SKP-1041 Phase 2 study in insomnia patients with MOTN awakenings

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News